Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States. Averin A, Quinn E, Atwood M, Weycker D, et al. Vaccine 2025;58:127191.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Averin A, Quinn E, Atwood M, Weycker D, et al. Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States. Vaccine 2025;58:127191.
PMID: 40383082